Loading...
Pharma Equity Group
powered by Stokk.io

Investor Presentation

Tue, 11 Jun, 2024, 13:00 – 14:00
This event has ended. Sign up below to watch the recording.
Sign in to access all the features of the platform.

How does this Q&A work:

This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.

The company will address as many questions as possible, and focus on those questions most wanted by investors.

Speakers at this event:

Pernille Lyngholm-Kjærby
Commercial Relationship Director

4 Questions

L
L**** *****
June 11, 2024

What is the normal structure of a license agreement? - An initial one-time payment? - Annual royalty payments? If we use RNX-051 as a case, is it correct that a license agreement with a 10% market share (the market size has been communicated by the company in newsletters) and a 10% royalty rate will generate a substantial three-digit DKK million amount annually? (I am aware that analyses from financial institutions estimate both the market share and royalty rate to be higher.)

S
S**** *****
June 10, 2024

Analyst Group expects you to deliver the first revenue from royalties in 2025. That is already next year. When can one expect you to enter into partnership agreements with corresponding royalties if the first ones are already due in 2025?

A
A**** *****
June 10, 2024

Which companies are you looking at as potential partners?

A
A**** *****
June 10, 2024

When can we expect to see the first partner collaborations?